Drug intelligence / Profile preview

AR343

Development stage: Preclinical
Lead developer: Anshi Pharmaceutical
Modality: Small Molecules

Overview

AR343 is a small molecule drug candidate being developed by Anshi Pharmaceutical for the treatment of non-alcoholic steatohepatitis (NASH). As of early 2024, the program is in the IND-enabling stage of development. It is part of Anshi's metabolic disease pipeline, which focuses on addressing the silent epidemic of NASH. Specific details regarding the biological target, mechanism of action, and pharmacological profile of AR343 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on AR343.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR343.

Explore the full profile